Kazia Therapeutics LimitedKZIA
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · Australia · kaziatherapeutics.com
Sydney-based oncology biotechnology company developing therapies that reprogram cancer biology, including paxalisib and EVT801. Its American Depositary Shares are its primary traded line, listed on the Nasdaq Capital Market.
Key ratios
FCF / Sales
-758.4%TTM
2025
-725.9%2024
-386.2%2023
-1485844.4%
ROA
-64.3%2025
2024
-71.6%2023
-47.2%
ROE
-2634.3%2024
2023
-135.0%
Revenue growth
-24.2%TTM
2025
-26.3%2024
248000.0%2023
-90.0%
Recent news
Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium
Kazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation Conference
Kazia Therapeutics: Sovargen Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering
Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering
Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer
Track KZIA in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer